Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
6(27%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_2
9
41%
Ph phase_4
1
5%
Ph not_applicable
3
14%
Ph phase_3
8
36%

Phase Distribution

0

Early Stage

9

Mid Stage

9

Late Stage

Phase Distribution21 total trials
Phase 2Efficacy & side effects
9(42.9%)
Phase 3Large-scale testing
8(38.1%)
Phase 4Post-market surveillance
1(4.8%)
N/ANon-phased studies
3(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

22

all time

Status Distribution
Active(8)
Completed(3)
Other(11)

Detailed Status

unknown11
Recruiting4
Completed3
Active, not recruiting2
Not yet recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
6
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 29 (42.9%)
Phase 38 (38.1%)
Phase 41 (4.8%)
N/A3 (14.3%)

Trials by Status

active_not_recruiting29%
not_yet_recruiting15%
completed314%
recruiting418%
unknown1150%
enrolling_by_invitation15%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT07407205Not Applicable

Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer

Active Not Recruiting
NCT04004871Phase 2

Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma

Completed
NCT07088731Phase 2

Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Not Yet Recruiting
NCT04952597Phase 2

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Completed
NCT04543695Phase 2

A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

Active Not Recruiting
NCT06048926Not Applicable

Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Enrolling By Invitation
NCT05511623Phase 2

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Recruiting
NCT05980715Phase 3

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy

Recruiting
NCT05950087

Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy

Recruiting
NCT05374252Phase 3

Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients

Unknown
NCT03663764Phase 2

Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor

Unknown
NCT01066234Phase 2

Adjuvant CCRT vs CT in Minimal N2 NSCLC

Completed
NCT04747951Phase 4

Total Neoadjuvant Therapy in Rectal Cancer Treatment

Unknown
NCT04453813Phase 3

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Recruiting
NCT02076477Phase 3

The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer(NSCLC)

Unknown
NCT03672136Phase 2

Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients

Unknown
NCT03601988Phase 3

Phase III Trial of Adjuvant Chemo-radiotherapy After D2 Surgery of Gastric Cancer

Unknown
NCT03177382Phase 3

Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors

Unknown
NCT03071198Not Applicable

Clinical Effect of Neoadjuvant Hierarchical Treatment Based on Chemotherapy

Unknown
NCT03058432Phase 2

Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Unknown

Drug Details

Intervention Type
RADIATION
Total Trials
22